Stock Stories

A pipeline of blockbuster products will help the household-name healthcare brand withstand a $1.5m baby powder asbestos scare that has buffeted its share price.

The competition watchdog may have raised a red flag over the proposed tie-up between telcos TPG and Vodafone but there’s still life in the deal, says Morningstar.

The RBA's December minutes showed members worrying over tightening credit and sluggish consumption.

The FAANGs have been priced for perfection at a time when their outlook is as challenging as it has ever been, writes Aberdeen's Karolina Noculak.

State Street Global Advisors' Kevin Anderson says 2019 will be volatile - but there will also be opportunities for investors who are ready to pivot.

Crown Resorts' dominance in VIP gaming at its new Sydney casino and an influx in Chinese tourists will boost the company's earnings and ensure its competitive edge over rival Star. 

The intensifying debate over franking credits topped our coverage last week, alongside the growing concerns about Australia's housing market, and our survey of the top stockpickers for 2018.

Australian shares are set for an early dive after Wall Street fell in late-week trade, with growth concerns and political uncertainty weighing on markets as Christmas approaches.

Drug distributor Australian Pharmaceutical Industries has offered about $727 million to buy all of rival Sigma Healthcare, aiming to consolidate in the face of increased competitive and regulatory pressures.

Shares in global travel agent Flight Centre are overvalued, trading at a 27 per cent premium to their $38 fair value estimate, according to Morningstar equity analyst Brian Han.